OPEN Foundation

OPEN Foundation

Psychobiology of Drug-Induced Religious Experience: From the Brain 'Locus of Religion' to Cognitive Unbinding

Abstract

The recent interest in the psychopharmacological underpinnings of religious experiences has led to both the laboratory characterizations of drug-induced mystical events and psychobiological models of religious experiences rooted in evolution and fitness. Our examination of this literature suggests that these theories may be congruent only within more modern religious and cultural settings and are not generalizable to all historical beliefs, as would be expected from an evolutionarily conserved biological mechanism. The strong influence of culture on the subjective effects of drugs as well as religious thoughts argues against the concept of a common pathway in the brain uniquely responsible for these experiences. Rather, the role of personal beliefs, expectations and experiences may interject bias into the interpretation of psychoactive drug action as a reflection of biologically based religious thought. Thus, psychobiological research proposing specific brain mechanisms should consider anthropological and historical data to address alternative explanations to the “fitness” of religious thought. A psychobiological model of the religious experience based on the concept of cognitive unbinding seems to accommodate these data better than that of a specific brain locus of religion.

Nencini, P., & Grant, G. A. (2010). Psychobiology of Drug-Induced Religious Experience: From the Brain ‘Locus of Religion’ to Cognitive Unbinding. Substance Use & Misuse, 45(13), 2130–2151. http://dx.doi.org/10.3109/10826081003713803
Link to full text

Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine

Abstract

Ayahuasca, also known as caapi or yage among various South American groups, holds a highly esteemed and millennia-old position in these cultures’ medical and religious pharmacopeia. There is now an increasing interest in the potential for modern medical applications of ayahuasca, as well as concerns regarding its increasing potential for abuse. Toxicological and clinical research to address these issues will require information regarding its metabolism and clearance. Thus, a rapid, sensitive and specific method for characterization and quantitation of the major constituents and of the metabolites of ayahuasca in urine is needed. The present research provides a protocol for conducting such analyses. The characteristics of the method, conducted by sample dilution and using HPLC–electrospray ionization (ESI)–selected reaction monitoring (SRM)–tandem mass spectrometry, are presented. The application of the analytical protocol to urine samples collected from three individuals that were administered ayahuasca has also been demonstrated. The data show that the major metabolite of the hallucinogenic component of ayahuasca, N,N-dimethyltryptamine (DMT), is the corresponding N-oxide, the first time this metabolite has been described in in vivo studies in humans. Further, very little DMT was detected in urine, despite the inhibition of monoamine oxidase afforded by the presence of the harmala alkaloids in ayahuasca. The major harmala alkaloid excreted was tetrahydroharmine. Other excretion products and metabolites were also identified and quantified. The method described would be suitable for use in further toxicological and clinical research on ayahuasca.

McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R., & Barker, S. A. (2011). Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomedical Chromatography, 25(9), 970-984. 10.1002/bmc.1551
Link to full text

Trouw: Ecstasy tegen PTSS

In de aanloop naar ons congres, dat afgelopen weekend plaatsvond, publiceerde dagblad Trouw al een artikel waarin Joost Breeksema (voorzitter van Stichting OPEN) uitvoerig aan het woord komt. Vandaag bericht de krant over het op het congres gepresenteerde onderzoek van Peter Oehen, naar de mogelijkheid om posttraumatische stressstoornis (PTSS) te behandelen met MDMA.

Trouw: “Uit het onderzoek bleek dat patiënten na het gebruik van MDMA minder last van angst hebben en beter in staat zijn negatieve gevoelens te tolereren. Bovendien voelen ze minder emotionele en fysieke pijn.”

Trouw: Ecstasy against PTSD

In anticipation of our conference, which took place last weekend, newspaper Trouw published an article in which Joost Breeksema (president of the OPEN Foundation) is interviewed. Today the newspaper writes about the research into the treatment of PTSD with MDMA that Peter Oehen presented at the conference. 

Trouw: “The study showed that patients, after the treatment with MDMA, experienced less anxiety and were better able to tolerate negative emotions. Moreover, they experienced less emotional and physical pain.”

Konstantin Kuteykin-Teplyakov – Molecules of Mysticism: Pharmacology Meets Anthropology

“Molecules of mysticism” are chemical substances that are able to induce mystical experience, increasing the feeling of closeness to the god (entheogens) or to other people (empathogens). It is quite likely, that every mystical experience is mediated chemically, either by some substances of external origin or by endogenous molecules produced directly in the brain. There are plenty of chemical structures, associated with entheogenic and empathogenic properties, and their action involves the release of other neurotransmitters, binding to many brain receptors (5-HT2a, 5-HT2c, 5-HT1a, CB1, NMDA, mAChR, etc.) followed by activation of several signal transduction pathways and alterations in gene transcription profile. Additionally, the mechanisms of several adverse effects for entheogens and empathogens have been elucidated during the last years. Considering that “molecules of mysticism” works not only and not so much on the body level, but mainly on consciousness and behaviour, and given the intrinsic difficulties associated with lab-based studies of scheduled substances on human beings, the methods of social anthropology (observation during fieldwork, surveys, interviews, and analysis of reports) might be used to supplement the classical pharmacological methodology. Web2.0 approach, based on content generated by users (like forums, wikis, online-based databanks of “trip reports”, multimedia-sharing services etc.), also may serve as a valuable tool and information source to study the relationship between drugs and humans.

About Konstantin Kuteykin-Teplyakov

Konstantin Kuteykin-Teplyakov, PhD, investigates the relationship between human beings and chemical substances by combining the methods of pharmacology and anthropology, with a special focus on Web 2.0 technologies. During his work as a researcher in Russia and Germany, he studied the molecular mechanism of brain function, as well as the implication of progress in pharmacology for modern society.

Torsten Passie – Astonishing Similarities of Physiological and Psychoactive Drug Induced States

Dr. Passie completed his training as a specialist in psychiatry and psychotherapy as well as his academic work at the Psychiatric University Hospital Zurich, in practice by Prof. Hans Carl Leuner in Göttingen and Hannover Medical School. He wrote his doctorate on existential aspects of psychiatric disorders and habilitation of altered states of consciousness. Prior to joining Oberberg, Dr. Passie was the Chief Physician of the Department of Psychiatry, Social Psychiatry and Psychotherapy, and Medical Director of the Hannover Centre of the Federal German model project for heroin assisted treatment of opiate addicts at the Medical University of Hannover.

Joe Bicknell – Cognitive Phenomenology of the Psychedelic Experience

Psychedelic phenomenology deals with the phenomenal content of psychedelic tripping, thus phenomenology approaches psychedelics from the reverse direction of the scientific approach, because instead of looking at the structures of physical brain chemistry and drug chemistry as scientists do, phenomenologists instead examine the structures of consciousness itself. The main concern of my research is the cognitive mechanisms that underlie the process of psychedelic mental transformation; that is, the transition from one worldview to another during the course of psychedelic exploration. An important aspect of this research is a revival of the old conception of psychedelic drugs as ‘psychotomimetic’, the trip experience is essentially a kind of temporary psychosis (that is, a temporary disconnection or disengagement from ordinary intersubjective reality). The core concept behind an understanding of psychedelic phenomenology is that of cognitive ‘hyperreflexivity’ (or ‘dissociation’). During psychedelic experiencing, consciousness is disconnected from external reality to some degree, and is concomitantly focused inwards towards the cognitive mechanisms that underlie subjectivity. This intensely inward-pointing perspective that is opened up during the trip experience creates the possibility for drastic reorganisation of psychological structures (specifically, the matrices of cognitive associations that hold together the sense of stable self-identity in the ordinary state of consciousness) which results in profound re-conception of ideas about the self and its relationship to time and the world.

David Luke – Exploring Exceptional Human Experience on Psychedelics: Ayahuasca, Telepathine and Parapsychology

The Amazonian sacramental decoction, ayahuasca (containing an alkaloid once called telepathine by Westerners), has been used by indigenous shamans and healers for several millennia. Apparently, for the explicit purposes of accessing altered states conducive to clairvoyance, precognition, telepathy, out-of-body travel, psychic diagnosis, psychic healing, and spirit communication. It has been argued that the endogenous neurochemicals present in this brew also play a primary neurological role in the occurrence of spontaneous parapsychological phenomena. However, although the neurobiological, anthropological and phenomenological evidence for this hypothesis is promising, the experimental parapsychological evidence to date is scant, poorly controlled, and inconclusive. Consequently, a recent parapsychological field study conducted in South America aimed to test the hypothesis that the ingestion of ayahuasca can increase performance on a task designed to measure precognition – the supposed ability to predict the future without recourse to any prior knowledge. The methods used and the results of this research project are discussed, along with the implications for neuroscience, medicine, parapsychology, philosophy of mind and psychedelic research.

About David Luke

David Luke, PhD, is currently President of the Parapsychological Association, the international professional body for researchers in this field, and Senior Lecturer in Psychology at the University of Greenwich, UK, where he teaches an undergraduate course on the Psychology of Exceptional Human Experiences. He is also Research Associate at the Beckley Foundation, Oxford, UK, which promotes research into the neuroscience of consciousness and its altered states, and he is a guest lecturer at the University of Northampton, UK. As a writer and researcher he has a special interest in altered states of consciousness and he has studied ostensibly paranormal phenomena and techniques of consciousness alteration from every continent of the globe, from the perspective of scientists, shamans and Shivaites.

Klaas Pieter van der Tempel – Psychedelic Consciousness and the Future of Academia

How does the psychedelic experience affect the knowledge and motivation of the scientist? And what does this mean for academia in general? To answer such questions, this presentation will focus on the master’s thesis “How to Go Out of Your Mind and Come Back Again” as well as the challenges faced while communicating psychedelic consciousness to the academic elite of the Netherlands. As a historical and philosophical study, this research attempts to place the psychedelically experienced scientist into a modern context where counterculture, psychedelics, and mainstream science meet.

Katharina Kirchner – LSD-assisted Psychotherapy. First Results from the Swiss Follow-up Study

After more than 40 years the first study employing LSD in psychotherapy is being conducted in Switzerland. 12 persons suffering from a life-threatening disease and an anxiety disorder are having the possibility to receive 200µg of LSD in a therapeutic setting. This talk will present the methodology and set-up of the study lead by Dr. P. Gasser. Furthermore the results from the pilot interviews of the follow-up study will be debuted. The interviews were conducted approximately one year after finishing the therapy and were aimed to reveal effects on daily life and long-term changes. Even though it is too early to make generally valid statements, first impressions from the client-centered research give valuable ideas for further research and indicate potential problems.

About Katharina Kirchner

Katharina Kirchner is currently involved with the Multidisciplinary Association for Psychedelic Studies (MAPS) as an assistant to Dr. P. Gasser for the study of “LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life-threatening diseases”. She conducted her master thesis in “LSD-supported psychotherapy, effects on daily life and long term changes”, supervised by Dr. P. Gasser & Dr. R. Stohler. Prior she joined a research project in Harare, Zimbabwe, for two months, which concerned the social- psychological evaluation of the implementation of solar disinfected water (SODIS)-strategy, in cooperation with UZH, ETH Zürich and EAWAG.

interested in becoming a trained psychedelic-assisted therapist?

Indigenous Talk: Fulni-ô Culture & Jurema - Online Event - Dec 12th